Unmasking HCM in Patients With Preserved EF: Diagnostic Clarity, Evolving Evidence, and Emerging Therapeutic Strategies
October 10, 2026 Multiple locations available
Navigating Chronic Anticoagulation Reversal in Cardiothoracic Surgery
Brian P. McDonough, MD, FAAFP
Ahmet Kilic, MD FACS
Heart Transplant in ATTR-CM: A New Look at Referral and Candidacy
Steve Jackson, PharmD
Alex Reyentovich, MD
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
M. Melih Dogan, MD
Reducing Cardiovascular Risk in Adult Survivors of Childhood Cancer
Stephanie Dixon, MD, MPH
Adapting CV Risk Reduction Strategies for Cancer Survivorship
A Long-Term View of Cardiovascular Risk After Cancer Treatment
APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
Erik Stroes
Advancing ATTR-CM Identification: Early Findings from TRACE-AI
Bruno Batinica, MD
Exploring AI-Powered ATTR-CM Detection
Plozasiran for Severe Hypertriglyceridemia: 12-Month Results From the SHASTA-3 and SHASTA-4 Trials at ESC
Prof. dr. Gerald Watts
Anticoagulation Reversal Decisions in Cardiothoracic Surgery: Case-Based Insights
Charles Turck, PharmD, BCPS, BCCCP
Akshay Kumar, MD
New Universal Definition Reframes Heart Failure Beyond Ejection Fraction
Ryan Quigley
A More Complete View of Cardiovascular Risk in Women
Noel Bairey Merz, MD
A Systematic Framework for Pediatric Acute Decompensated Heart Failure
ACACIA-HCM: What Do the Phase 3 Results Show?
Ahmad Masri, MD, MS
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.